Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD.

A recent review of 41 femoral arteriograms carried out at the Memorial Hospital, Worcester, indicated that 76 per cent showed an obstruction of the superficial femoral artery at this level (Fig.

Few disciplines in medicine have evolved as rapidly as endovascular therapy for arterial and venous disease. In this issue of ...

Following the successful completion of SIRONA--the largest superficial femoral artery (SFA) trial comparing our device against paclitaxel drug-coated balloons (DCBs), which demonstrated non ...

PTAB with the DETOUR System offers a novel approach to treating complex peripheral arterial disease (PAD), enabling physicians to percutaneously bypass lesions in the superficial femoral artery by ...

SELUTION SLR™ Drug-Eluting Balloon (DEB) achieves amongst the highest reported patency for any drug-eluting or drug-coated technology at 3 years in the SELUTION SFA Japan Trial, with 81.5% ...